Zentalis Pharmaceuticals, Inc. Share Price & Technical Analysis
ZNTL · $3.58 (0.00%)
Healthcare / Biotechnology
$3.58
0.00%
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenoserti…
Price chart
Seasonality
Jun has 2 positive and 2 negative years (last 5 years shown)
-12% return in Jun, -19% avg return in past 3 year Jun month.
133% return in 2026, -45% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 71% | 0% | 0% | 74% | 0% | -12% | – | – | – | – | – | – | 133% |
| 25 | -45% | 24% | -24% | -12% | -20% | 0% | 27% | 31% | -12% | 0% | -7% | 0% | -38% |
| 24 | -20% | 25% | 6% | -29% | 7% | -66% | -5% | -10% | 9% | -27% | 33% | -19% | -95% |
| 23 | 16% | -20% | -9% | 28% | 18% | 8% | -5% | 2% | -25% | -18% | -31% | 35% | -1% |
| 22 | -32% | -12% | -8% | -43% | -8% | 15% | 4% | -7% | -18% | 13% | -13% | -9% | -119% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$260.54M
P/E ratio
—
52W high
$6.95
52W low
$1.13
Volume
4,40,310
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Zentalis Pharmaceuticals, Inc. share price today?
- Zentalis Pharmaceuticals, Inc. (ZNTL) last traded around $3.58 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ZNTL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ZNTL. Download the app for real-time alerts.
- How can I analyze Zentalis Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.